Overview

Evaluation of Tirzepatide as an Adjunct to Buprenorphine for the Treatment of Opioid Use Disorder

Status:
NOT_YET_RECRUITING
Trial end date:
2027-06-30
Target enrollment:
Participant gender:
Summary
The primary objective of this research study is to evaluate the effect of tirzepatide, relative to placebo, as an adjunct to BUP on retention, substance use, and sleep outcomes in individuals with OUD.
Phase:
PHASE2
Details
Lead Sponsor:
T. John Winhusen, PhD
Collaborator:
National Institute on Drug Abuse (NIDA)
Treatments:
Tirzepatide